3 results
Approved WMORecruiting
Subjects randomized to the placebo treatment are unlikely to benefit from the study. However, OAB is not a life-threatening disease and it is not expected that a 12 to 15 week exposure to placebo treatment will have a negative impact on disease…
Not approvedWill not start
Change from baseline in regional cerebral blood flow in response to various visual stimuli ascertained by Positron Emission Tomography scan after 8 weeks of flibanserin 100 mg treatment.
Approved WMOCompleted
Primary Objective:To evaluate the efficacy and safety of solifenacin succinate o.d. in children and adolescents with OABSecondary Objective:To perform population pharmacokinetics after multiple-dose administration.